Zentalis Pharmaceuticals Inc. (ZNTL)
ZNTL trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1725160/000172516026000014/0001725160-26-000014-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ZNTL on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001725160 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DELAWARE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$137.1M |
| Operating income | -$152.8M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | -100.0% |
| Cash | $36.0M |
| Total assets | $289.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Substantial doubt about an entity's ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year from the financial statements issuance date." | 10-Q 2026-11-09 |
| Cash and burn | $24.0M cash; operating cash flow -$33.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 98,265,863 (2026-11-04); 72,250,779 a year earlier; 70,765,771 three years earlier. | Cover page 2026-11-04 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-08-14 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Diego, California, United States | PCAOB Form AP 2026-04-10 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $22.9M, sold $10.1M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$28.8M | -$32.7M | $24.0M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | Not filed | -$42.3M | -$37.2M | $24.8M | No debt tags | Needs four quarters | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | Not filed | -$35.4M | -$33.0M | $31.9M | No debt tags | Needs four quarters | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | $0 | -$35.2M | -$30.9M | $36.0M | No debt tags | $0 | 10-K 2026-03-26 |
| Q3 2025 2025-09-30 | $0 | -$26.7M | -$27.0M | $39.1M | No debt tags | $26.9M | 10-Q 2025-11-10 |
| Q2 2025 2025-06-30 | $0 | -$26.9M | -$34.7M | $37.6M | No debt tags | $26.9M | 10-Q 2025-08-06 |
| Q1 2025 2025-03-31 | $0 | -$48.3M | -$32.6M | $41.9M | No debt tags | $26.9M | 10-Q 2025-05-14 |
| Q4 2024 2024-12-31 | $26.9M | -$47.5M | -$39.7M | $33.9M | No debt tags | $67.4M | 10-K 2026-03-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-08-14 |
| Latest annual report | 10-K | 2026-03-26 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-05-27 |
Source: SEC EDGAR submissions feed, 550 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.2% |
| 1 month | -29.2% |
| 3 months | -59.0% |
| Year to date | +25.9% |
| 1 year | +28.8% |
| From 52-week high | -74.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BBOT | BridgeBio Oncology Therapeutics Inc. Common Stock | $1.98 | -7.48% | $158.9M |
| ADCT | ADC Therapeutics SA Common Shares | $1.25 | -6.72% | $159.7M |
| ABEO | Abeona Therapeutics Inc. | $2.60 | +7.44% | $148.6M |
| ELDN | Eledon Pharmaceuticals Inc. | $1.97 | -6.86% | $166.4M |
| PRQR | ProQR Therapeutics N.V. | $1.18 | -16.31% | $166.5M |
| VRXA | Veraxa Biotech AG | $1.04 | -5.86% | $147.8M |
| PYXS | Pyxis Oncology Inc. | $1.41 | -10.76% | $168.6M |
| ORMP | Oramed Pharmaceuticals Inc. | $3.90 | +5.12% | $169.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier